Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Notes Payables (2016 - 2025)

Marimed (MRMD) has disclosed Notes Payables for 12 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Notes Payables fell 50.2% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 50.2% year-over-year, with the annual reading at $2.6 million for FY2025, 50.2% down from the prior year.
  • Notes Payables for Q4 2025 was $2.6 million at Marimed, up from $2.3 million in the prior quarter.
  • The five-year high for Notes Payables was $5.1 million in Q4 2024, with the low at $4856.0 in Q1 2021.
  • Average Notes Payables over 5 years is $1.7 million, with a median of $890000.0 recorded in 2023.
  • The sharpest move saw Notes Payables crashed 99.98% in 2021, then skyrocketed 2085.5% in 2024.
  • Over 5 years, Notes Payables stood at $1.4 million in 2021, then soared by 167.66% to $3.8 million in 2022, then plummeted by 80.84% to $723000.0 in 2023, then skyrocketed by 608.99% to $5.1 million in 2024, then plummeted by 50.2% to $2.6 million in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $2.6 million, $2.3 million, and $3.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.